Legend Biotech Corporation (LEGN)

業務介紹

傳奇生物科技有限公司是一家臨床階段生物製藥公司，通過其子公司在美國、中國和國際市場從事新型細胞療法在腫瘤學和其他領域的發現和開發。其主要產品候選藥LCAR-B38M是一種嵌合抗原受體，用於治療多發性骨髓瘤（MM），並與標準三聯療法進行比較，用於治療反對Revlimid的多發性骨髓瘤。該公司還擁有一系列早期自體產品候選藥，正在進行I期臨床試驗，用於治療胃癌和T細胞淋巴瘤。此外，該公司還正在開發針對非霍奇金淋巴瘤、弥漫性大B細胞淋巴瘤和急性淋巴白血病的CAR-T產品候選藥，目標為CD20/CD22/CD19。此外，該公司還有早期臨床前和臨床開發的產品候選藥，用於治療實體腫瘤和傳染病。該公司與詹森生物技術公司簽訂了合作和許可協議，共同開發和商業化ciltacabtagene autoleucel。傳奇生物科技有限公司成立於2014年，總部位於新澤西州的Somerset。傳奇生物科技有限公司是Genscript生物科技有限公司的子公司。

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

公司網址

https://www.legendbiotech.com